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Abstract
Background: In Canada, systematic efforts for controlling antibiotic resistance began in 1997 following a national
Consensus Conference. The Canadian strategy produced 27 recommendations, one of which was the formation of
the Canadian Committee on Antibiotic Resistance (CCAR). In addition several other organizations began working
on a national or provincial basis over the ensuing years on one or more of the 3 identified core areas of the
strategy. Critical evaluation of the major programs within Canada which focused on antimicrobial resistance and
the identified core components has not been previously conducted.
Findings: Data was collected from multiple sources to determine the components of four major AMR programs
that were considered national based on their scope or in the delivery of their mandates. Assessment of program
components was adapted from the report from the International Forum on Antibiotic Resistance colloquium. Most
of the programs used similar tools but only the Do Bugs Need Drugs Program (DBND) had components directed
towards day cares and schools. Surveillance programs for antimicrobial resistant pathogens have limitations and/or
significant sources of bias. Overall, there has been a 25.3% decrease in oral antimicrobial prescriptions in Canada
since 1995, mainly due to decreases in b lactams, sulphonamides and tetracyclines in temporal association with
multiple programs with the most comprehensive and sustained national programs being CCAR and DBND.
Conclusions: Although there has been a substantial decrease in oral antimicrobial prescriptions in Canada since
1995, there remains a lack of leadership and co-ordination of antimicrobial resistance activities.
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Introduction
Antimicrobial resistance (AMR) has dramatically
increased since the 1990s, and it is widely acknowledged
to be a global public health threat [1-4]. In Canada, sys-
tematic efforts for controlling antibiotic resistance began
in 1997 following a national Consensus Conference held
in Montreal entitled “Controlling Antimicrobial Resis-
tance: An Integrated Action Plan for Canadians” [5].
The conference, co-sponsored by Health Canada and
the Canadian Infectious Disease Society, developed a
plan which emphasized 3 core areas: antimicrobial stew-
ardship, surveillance to monitor resistance trends and
infection prevention and control (IPC). The Canadian
strategy produced 27 recommendations, one of which
was the formation of the Canadian Committee on
Antibiotic Resistance (CCAR), a multidisciplinary com-
mittee which performed a collating and coordinating
role for stakeholder groups across Canada. In addition
several other organizations began working on a national
or provincial basis over the ensuing years on one or
more of the 3 identified core areas formulated during
the Consensus Conference. Critical evaluation of the
major programs within Canada focused on antimicrobial
resistance and the identified core components has not
been previously conducted. This paper describes the
identification of major AMR programs in Canada
between 1995 and 2010 and critically examined the
components of surveillance and stewardship.
Methods
Data was collected from multiple sources to determine
the components of four major AMR programs that were
considered national based on their scope or in the deliv-
ery of their mandates, including the Canadian Committee
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on Antibiotic Resistance (CCAR), Do Bugs Need Drugs
(DBND) - originating in the province of Alberta and
adopted in the provinces of British Columbia and Sas-
katchewan, National Information Program on Antibiotics
(NIPA) and the National Collaborating Centre for Infec-
tious Diseases (NCCID), whose mission is to protect the
health of Canadians by facilitating the use of evidence
and emerging research on infectious diseases to inform
public health programs and policy. Sources of data col-
lection for Antimicrobial Resistance (AMR) Programs
included the following: review of CCAR Updates in the
Can J Med Micro Infect Dis 1998-2009; review of all pro-
gram websites; and a review of the CCAR led “Pan Cana-
dian Stakeholder Consultations on Antimicrobial
Resistance 2009”. Assessment of program components
was adapted from the report from the International
Forum on Antibiotic Resistance (IFAR) colloquium [6].
Through an agreement with Intercontinental Medical
Statistics (IMS) HEALTH Canada and its Compuscript
database, complete antimicrobial consumption data on
all classes of oral antimicrobials in Canada was provided
to CCAR up until 2004 and to the Canadian Integrated
Program for Antimicrobial Resistance from 2000-2010
[7]. The IMS HEALTH Canada Compuscript database
provided continuous surveillance data of the total num-
ber of antibiotic prescriptions dispensed in Canadian
retail pharmacies based on a representative sample of
2000 pharmacies stratified by province, store type and
size [7]. Population data by year was collected from Sta-
tistics Canada [8]. Data sources for surveillance of key
marker organisms was collected from multiple sources
including a publication by the CCAR International
Report Card Working Group [9] and a survey of multiple
Canadian websites that reported the results of
Table 1 National AMR Programs in the Community in Canada 1995-2010
CCAR DBND NIPA NCCID
Years 1998-2009 From 1998 2001-2006 From 2008
Scope National Provincial National National
Duration 12 yrs Ongoing 5 yrs Ongoing
Funding Federal Gov’t Provincial Pfizer Federal Gov’t
Public Communications
Pamphlets/brochures Yes Yes Yes Yes
Press conferences Yes Yes Yes Yes
Posters Yes Yes Yes Yes
Television/Radio No Yes Yes No
Video (eg, clinic room) No Yes No No
Website Yes Yes Yes Yes
Day-care programme No Yes No No
School programme No Yes No No
Professional Communications
Doctors/Pharmacists/Nurses Yes* Yes Yes Yes
Scientific journal articles Yes No Yes Yes
Treatment guidelines Endorsed DBND Yes No No
Letters to doctors Yes Yes No No
Toolkits Distributed Yes† No No No
Educational outreach Yes Yes No No
Feedback No Yes No Yes
Undergraduate curriculum Yes Yes No No
Antibiotic prescription pads Yes Yes Yes No
Symptomatic therapy scripts Evaluation Yes Yes Yes Yes
Controls for evaluation No Yes No No
Patient/physician knowledge No Yes Yes No
Antibiotic use Yes‡ Yes No No
Resistance rates Yes Yes Yes No
Clinical outcomes No No No No
CCAR: Canadian Committee on Antibiotic Resistance; DBND: Do Bugs Need Drugs?; NIPA: National Information Program on Antibiotics; NCCID: National
Collaborating Centre for Infectious Diseases
*Included information for veterinarians
† all 56,000 physicians in Canada
‡ obtained agreement with IMS HEALTH Canada to provide up-to-date national and regional antibiotic consumption data through its Compuscript database
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surveillance data. Critical evaluation and assessment of
bias of surveillance with respect to reporting, objectives,
host population, sampling, population demographics,
organisms, isolate collection, susceptibility testing, data
handling and analysis was retrieved from Stephen et al.
[9]
Table 2 Antimicrobial Resistance Surveillance in Canada
Program name Funding Focus Assessment
Canadian Integrated Program for Antimicrobial Surveillance (CIPARS)
http://www.phac-aspc.gc.ca/cipars-picra
PHAC Food borne pathogens
Antimicrobial usage
Comprehensive Reliance on passive
reporting for Salmonella




Focused on tertiary care
Canadian National Centre for Streptococcus http://www2.provlab.ab.
ca/ncs/ncs.htm
PHAC Group A streptococci Not representative
Canadian Tuberculosis Laboratory Surveillance System http://www.
phac-aspc.gc.ca/publicat/tbdrc01/index.html
PHAC M. tuberculosis




Biased sampling Potential COI




Biased sampling Potential COI
PHAC: Public Health Agency of Canada; COI: Conflict of interest
Oral Antibiotic Scripts/1000 Population 1995-2010* 
*Data from IMS Health Canada provided to CCAR and CIPARS
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Figure 1 Oral antimicrobial scripts in Canada and temporal relationship to AMR Programs.
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Results
A summary of the components of four major AMR pro-
grams that were profiled are provided in Table 1.
Although the DBND Program was initially provincial in
scope, it was included in the evaluation since other pro-
vinces began using the program or portions of the pro-
gram. Three of the programs had governmental funding
and one was funded by a pharmaceutical company and
had a very short duration. Most of the programs used
similar tools but only the DBND Program had compo-
nents directed towards day cares and schools. Only the
CCAR Program distributed “toolkits” to all Canadian
physicians. The DBND program had the most rigorous
evaluation of its activities.
The sources of antimicrobial resistance surveillance,
their funding source and sources of bias are illustrated
in Table 2. Unfortunately all the surveillance programs
have limitations and/or significant sources of bias.
Although the CIPARS surveillance is the most compre-
hensive, it is not population based and focuses on
pathogens associated with food-borne illnesses [10].
The surveillance results of total oral antimicrobial
scripts in Canada, adjusted by population and their tem-
poral relationship to AMR Programs between 1995-2010
and the breakdown of scripts by class are illustrated in
Figures 1 and 2. Most of the programs used similar
tools but only the DBND Program had components
directed towards day cares and schools. Most of the
programs used similar tools but only the DBND Pro-
gram had components directed towards day cares and
schools. There appears to be a corresponding increase
in the use of quinolones and macrolides, much of this
driven by increases in newer generation agents in each
of the two categories [10].
Conclusions
Although the findings from this report focus on only a
few nationally focused efforts that took place over the
last 15 years, a number of additional provincial, regional
and local efforts were also undertaken across Canada
[11-14]. Most of the efforts focused on communications
to physicians, pharmacists and the general public. Over-
all, there has been a 25.3% decrease in oral antimicrobial
prescribing in Canada since 1995, mainly due to
decreases in b lactams, sulphonamides and tetracyclines,
in temporal association with multiple programs with the
most comprehensive and sustained national programs
being CCAR and DBND. It is acknowledged that this is
Oral Antibiotic Scripts by Major Class 1995-2010* 
*Data from IMS Health Canada provided to CCAR and CIPARS 
   Population data from Statistics Canada 
BSP = Broad Spectrum Penicillins  
TMP-SMX =Trimethoprim-Sulfamethoxazole 
Figure 2 Oral antimicrobial prescribing by major class in Canada 1995-2010.
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only an association and may be a spurious finding but
the consistent and sustained observations over 15 years
provide arguments that the AMR programs have had an
impact [4].
The findings also demonstrate that there is no popula-
tion based surveillance of common community pathogens
such as Streptococcus pneumoniae or Staphlyococcus aur-
eus where resistance is common. Reliance on Pharma
funded surveillance is not comprehensive and has signifi-
cant difficulties with sampling bias [9]. There is a need for
a federally funded population based surveillance of com-
mon community pathogens rather than reliance on
Pharma funded surveillance.
Although the CIPARS Program offers a comprehen-
sive and co-ordinated approach to some AMR activities,
it is a limited focus. Currently, from the human perspec-
tive, there is a distinct lack of leadership and co-ordina-
tion of AMR activities at the national level in Canada
and concerns may be raised about losing some of the
gains that have been made over the years.
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